EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Metabolism-based scoring of cutaneous squamous cell carcinoma to predict tumour features and responses to treatment with dihydroorotate dehydrogenase inhibitors

Lea Dousset, Ferial Khalife, Domitille Chalopin-Fillot iD, Benjamin Dartigues iD, Fatima Naji, Walid Mahfouf, Elodie Muzotte, Benoît Rousseau, Nivea Amoedo iD, Stéphane Claverol iD, Mathieu Bondaz, Fanny Beltzung und 8 weitere

British Journal of Dermatology · 2025

DOI: 10.1093/bjd/ljaf253 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Dermatology, 2025. Verfasst von Lea Dousset und 19 weiteren Autor:innen. Beteiligte Einrichtung: University of Bordeaux, Inserm, BRIC, UMR 1312, Bordeaux, France. Hauptthemen laut MEDLINE: Skin Neoplasms, Oxidoreductases Acting on CH-CH Group Donors, Carcinoma, Squamous Cell, Enzyme Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Fondation ARC pour la Recherche sur le Cancer, institutional, INSERM.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Alteration in metabolic activities is a critical step in cancer progression. Myriad metabolic-based therapy options are increasingly being proposed for human tumours. However, emerging evidence highlights interpatient metabolic heterogeneity and underscores the importance of metabolic phenotyping in cancer treatment.

Objectives

To investigate metabolic heterogeneity in cutaneous squamous cell carcinoma (cSCC) and its impact on cSCC characteristics and treatment responses.

Methods

We applied combined proteomic and bioenergetic analyses to patient samples representing various stages of cSCC, ranging from precancerous actinic keratosis to metastatic cSCC. To investigate the functional impacts of the identified metabolic heterogeneities on tumour characteristics and treatment responses, we used patient-derived tumour cell (PDC) and patient-derived xenograft (PDX) models by transplanting tumour cells and freshly resected patient tumours into immunocompromised mice.

Results

Three subgroups with low, medium and high metabolic scores, respectively, were identified across all stages of carcinogenesis. Functional analyses indicated that, in both models (PDC and PDX), the sensitivities of tumours to leflunomide, an inhibitor of dihydroorotate dehydrogenase (DHODH), were inversely correlated with their metabolic scores and directly correlated with DHODH protein expression level. Moreover, DHODH overexpression in nonresponding groups rendered them sensitive to leflunomide.

Conclusions

The findings demonstrate the relevance of metabolic profiling and scoring in the design of therapeutic approaches targeting the bioenergetic vulnerabilities of tumours and suggest DHODH as a promising therapeutic target in the low metabolic score subgroup of cSCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Skin NeoplasmsOxidoreductases Acting on CH-CH Group DonorsCarcinoma, Squamous CellEnzyme InhibitorsDihydroorotate DehydrogenaseHumansAnimalsLeflunomideXenograft Model Antitumor AssaysProteomicsFemaleMiceMale

Substanzen

Dihydroorotate DehydrogenaseOxidoreductases Acting on CH-CH Group DonorsLeflunomideEnzyme Inhibitors

Autor:innen und Institutionen

  • University of Bordeaux, Inserm, BRIC, UMR 1312, Bordeaux, France.
  • Dermatology Department, Bordeaux University Hospital, Saint-André Hospital, Bordeaux, France.
  • University of Bordeaux, CNRS, IBGC, UMR 5095, Bordeaux, France.
  • Animalerie A2, University of Bordeaux, Bordeaux, France.
  • Inserm U1211 Maladies Rares: Génétique et Métabolisme (MRGM), University of Bordeaux, Bordeaux, France.
  • CELLOMET, Bordeaux Centre of Functional Genomics, University of Bordeaux, Bordeaux, France.

ORCID-Profile: Domitille Chalopin-Fillot, Benjamin Dartigues, Nivea Amoedo, Stéphane Claverol, Marie-Laure Jullie, Alain Taieb, Laure Favot-Laforge, Marie Beylot-Barry, Macha Nikolski, Hamid-Reza Rezvani

Förderung

  • Fondation ARC pour la Recherche sur le Cancer
  • institutional
  • INSERM

Zitieren

APA

Dousset, L., Khalife, F., Chalopin-Fillot, D., Dartigues, B., Naji, F., Mahfouf, W., Muzotte, E., Rousseau, B., Amoedo, N., Claverol, S., Bondaz, M., Beltzung, F., Jullie, M. L., Vergier, B., Taieb, A., Favot-Laforge, L., Rossignol, R., Beylot-Barry, M., Nikolski, M., & Rezvani, H. R. (2025). Metabolism-based scoring of cutaneous squamous cell carcinoma to predict tumour features and responses to treatment with dihydroorotate dehydrogenase inhibitors. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljaf253

Vancouver

Dousset L, Khalife F, Chalopin-Fillot D, Dartigues B, Naji F, Mahfouf W, et al. Metabolism-based scoring of cutaneous squamous cell carcinoma to predict tumour features and responses to treatment with dihydroorotate dehydrogenase inhibitors. British Journal of Dermatology. 2025. doi:10.1093/bjd/ljaf253

BibTeX
@article{Dousset2025,
  author = {Dousset, Lea and Khalife, Ferial and Chalopin-Fillot, Domitille and Dartigues, Benjamin and Naji, Fatima and Mahfouf, Walid and Muzotte, Elodie and Rousseau, Benoît and Amoedo, Nivea and Claverol, Stéphane and Bondaz, Mathieu and Beltzung, Fanny and Jullie, Marie-Laure and Vergier, Beatrice and Taieb, Alain and Favot-Laforge, Laure and Rossignol, Rodrigue and Beylot-Barry, Marie and Nikolski, Macha and Rezvani, Hamid-Reza},
  title = {Metabolism-based scoring of cutaneous squamous cell carcinoma to predict tumour features and responses to treatment with dihydroorotate dehydrogenase inhibitors},
  journal = {British Journal of Dermatology},
  year = {2025},
  doi = {10.1093/bjd/ljaf253}
}
Kostenlos starten →